In line with previous studies reporting a prominent role for TET2-CHIP-driver mutations in atherosclerotic vascular diseases [2], in the never-smoking cohort, atherosclerotic polyvascular bed disease (defined as clinical disorders involving ≥ 2 vascular territories) was present in 34.5% (20/58) of patients carrying TET2 mutations compared with 12.3% (10/81) of patients carrying DNMT3A mutations (p = 0.002). Here, TET2 is linked to glycogen storage disease VI.